亚胺培南/西司他丁致中枢神经系统不良反应的文献分析  

Literature analysis of adverse drug reaction on central nervous system induced by imipenem/cilastatin

作　　者：倪文骐 熊琪 袁凤仪 陈頔[2] 朱峰 Ni Wenqi;Xiong Qi;Yuan Fengyi;Chen Di;Zhu Feng(Health Division of Guard Bureau,Joint Staff of the Central Military Commission,Beijing 100017,China;不详)

机构地区：[1]中央军委联合参谋部警卫局卫生保健处,北京100017 [2]北京医院药学部国家老年医学中心中国医学科学院老年医学研究院

出　　处：《中国临床保健杂志》2022年第1期91-94,共4页Chinese Journal of Clinical Healthcare

摘　　要：目的进一步了解亚胺培南/西司他丁中枢神经系统不良反应(ADR)的发生情况及危险因素,为临床合理用药提供参考。方法检索中国知网(CNKI)、万方数据库(Wanfang)、中国生物医学文献数据库(CBM)及维普数据库(VIP)中亚胺培南/西司他丁致中枢神经系统ADR的病例报道,并进行统计分析。检索时间为自该药上市以来至2021年5月1日。结果共纳入文献86篇,包含患者110例,其中男性62例(56.36%),女性48例(43.64%),年龄(64.22±21.29)岁,日剂量为(1.95±0.79)g,原患疾病以呼吸系统感染为主,不良反应多发生在用药2~6 d,临床主要表现为癫痫样症状(58.18%)和意识障碍(35.46%)。结论亚胺培南/西司他丁可导致中枢神经系统ADR。当患者合并有老年(>60岁)、肾功能不全、用法用量不适宜或中枢神经系统病史等危险因素时,临床使用应慎重,并加强不良反应监测,保障患者用药安全。Objective To further comprehend the adverse drug reaction(ADR)on central nervous system induced by imipenem/cilastatin and the risk factors.Methods Case reports of ADR on central nervous system induced by imipenem/cilastatin were retrieved from CNKI,Wanfang,CBM,and VIP databases until May 1,2021,and the case reports were analyzed.Results A total of 86 references were included.One hundred and ten patients were enrolled in this study.They comprised 62 men(56.36%)and 48 women(43.64%)with an average age of(64.22±21.29).The average dose of 110 patients was(1.95±0.79)grams.Most primary diseases were respiratory infections.ADR induced by imipenem/cilastatin mostly occurred within 2-6 days after medication.The clinical manifestations in most patients were epileptic symptoms(58.18%)and conscious disturbance(35.46%).Conclusions Imipenem/cilastatin has some ADR on central nervous system.When patients accompanied by risk factors such as advanced age(over 60),renal insufficiency,inappropriate usage and dosage,or history of central nervous system diseases,the its clinical application should be cautious,and the ADR monitoring should be strengthened to ensure the safety of patients.

关 键 词：药物相关性副作用和不良反应 中枢神经系统 评价研究 西司他丁 亚胺培南复方合剂 

分 类 号：R969[医药卫生—药理学]